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Chlordane, a human-made chemical mix-
ture of structurally similar organochlorines, 
was widely used on agricultural crops and 
as a termiticide in the United States until 
1988 (Abadin et al. 1994). Chlordane con-
sists of > 140 isomers; the most abundant 
include trans-chlordane, cis-chlordane, trans-
  nonachlor, beta-chlordane, and heptachlor. In 
humans the predominant chlordane-related 
contaminants detected are trans-nonachlor 
and oxychlordane, a major metabolite of the 
chlordanes and nonachlors (Dearth and Hites 
1991; Ivie 1973). Chlordanes have a 10- to 
20-year half-life in soil, and exposure as a 
result of termite treatment around dwellings 
may have continued for decades after applica-
tion (Bennett et al. 1974).
Chlordanes, specifically nonachlor deriv-
atives (trans-nonachlor and cis-nonachlor), 
have been among the organochlorines most 
consistently associated with testicular germ 
cell cancer (Cook et al. 2011). Of the four 
published studies evaluating serum chlor-
dane levels and testicular germ cell tumors 
(TGCT) (Biggs et al. 2008; Hardell et al. 
2003; McGlynn et al. 2009b; Purdue 
et al. 2009), three reported positive asso-
ciations with serum nonachlor. One was a 
retrospective evaluation in Sweden (Hardell 
et al. 2003), and two were prospective evalu-
ations, one in the United States and one in 
Norway (McGlynn et al. 2009b; Purdue et al. 
2009). In animal experiments, chlordane has 
been shown to interfere with steroid hormone 
metabolism, perhaps because of the induction 
of cytochrome oxidase enzymes (Welch et al. 
1971). Given the associations between chlor-
dane isomers and TGCT, it is reasonable to 
assume that chlordane levels might also be 
associated with other testicular dysgenesis 
syndrome disorders, namely cryptorchidism 
(failure of one or both testicles to descend 
into the scrotum) and hypospadias (urethral 
opening on the ventral side of the penis or on 
the perineum) (Skakkebaek 2003).
Cryptorchidism and hypospadias are com-
mon genital birth defects, affecting approxi-
mately 3–4% and 0.2–1% of male newborns, 
respectively. Increases in both congenital 
malformations have been reported in several 
but not all countries (Paulozzi 1999; Toppari 
et al. 2010). Both conditions can be outcomes 
of androgen insufficiency (Toppari et al. 
2010). Shared risk factors for cryptorchid-
ism and hypospadias include premature 
delivery, intrauterine growth restriction, and 
concomitant genital abnormalities (Toppari 
et al. 2010). The etiologic role of lifestyle and 
environmental exposures such as smoking and 
organochlorines has been evaluated in some 
studies, but few have evaluated the association 
between maternal chlordane levels and either 
male congenital anomaly. In the only pub-
lished report to date, Damgaaard et al. (2006) 
found a positive association between breast 
milk chlordane levels and cryptorchidism in 
sons. The paucity of data on the relation of 
chlordane isomers with male birth defects 
indicates the need for additional studies.
In a case–control study nested within a 
large prospective cohort of pregnant women, 
we evaluated whether levels of trans-nonachlor 
and oxychlordane in maternal third-trimester 
serum were associated with cryptorchidism or 
hypospadias among male children.
Materials and Methods
Study population. The Collaborative Perinatal 
Project (CPP) was a prospective study of neu-
rologic disorders and other conditions in chil-
dren (Niswander and Gordon 1972). From 
1959 to 1965, the study enrolled 48,197 
women upon presenting for prenatal care 
at 12 medical centers in the United States. 
Centers were located in Baltimore, Maryland; 
Boston, Massachusetts; Buffalo, New 
York; Memphis, Tennessee; Minneapolis, 
Minnesota; New Orleans, Louisiana; New 
York, New York (two centers); Philadelphia, 
Pennsylvania; Portland, Oregon; Providence, 
Rhode Island; and Richmond, Virginia. 
Eleven centers recruited participants from 
the prenatal clinics of a university hospital, 
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Ba c k g r o u n d: The etiologies of the male urogenital anomalies—cryptorchidism and hypospadias—
are poorly understood. Given positive associations between chlordane isomers and testicular germ 
cell tumors, it is reasonable to assume that chlordanes might also be associated with other testicular 
dysgenesis syndrome disorders, namely cryptorchidism and hypospadias.
oB j e c t i v e: To examine whether exposure to in utero chlordane is related to cryptorchidism and 
hypospadias, we evaluated levels of chlordane derivatives, trans-nonachlor and oxychlordane, among 
pregnant women enrolled in the Collaborative Perinatal Project (CPP).
Me t h o d s : From 1959 to 1965, the CPP enrolled pregnant women at 12 U.S. medical centers. 
We analyzed serum trans-nonachlor and oxychlordane levels measured in third-trimester serum 
from the mothers of 217 sons with cryptorchidism, 197 sons with hypospadias, and 557 sons with 
neither condition. Adjusted odds ratios (ORs) and 95% confidence intervals were calculated using 
conditional logistic regression.
re s u l t s: The quartile-specific ORs for cryptorchidism or hypospadias show no notable associations 
with trans-nonachlor or oxychlordane. Further, there were no significant trends with increasing 
quartile of maternal trans-nonachlor or oxychlordane level in either cryptorchidism or hypospadias 
(p-trend all > 0.45).
co n c l u s i o n s: The results do not support an association between chlordane levels and cryptorchid-
ism or hypospadias. It is unlikely that current chlordane exposure is related to the development of 
either anomaly, given that serum chlordane levels at the time of sample collection, the early 1960s, 
were considerably higher than levels at present.
key w o r d s : chlordanes, cryptorchidism, hypospadias, oxychlordane, pregnant women, prospective 
cohort, trans-nonachlor. Environ Health Perspect 120:478–482 (2012).  http://dx.doi.org/10.1289/
ehp.1103936 [Online 7 September 2011]Chlordanes and male congenital anomalies
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and one (Buffalo) recruited from 13 pri-
vate obstetric practices. The study was not 
intended to be representative of the United 
States, and each clinical site had its own sam-
pling approach (varying from 10 to 100% of 
eligible women, either by enrolling a random 
or systematic sample or all women).
Women were ineligible if they were incar-
cerated, planned to leave the area after deliv-
ery, planned to place their child for adoption, 
or if they delivered on the day they were 
recruited for the study. Four percent of the 
participants were lost to follow-up before 
delivery. As part of data collection, the moth-
ers were asked to donate non  fasting blood 
samples at approximately 8-week intervals 
throughout their pregnancies. Serum samples 
were stored in glass vials at –20°C with no 
recorded thaws.
There were 142,130 pregnancies among 
the 48,197 women, including 54,390 preg-
nancies prospectively (observed) captured by 
the CPP. The children were systematically 
assessed for the presence of birth defects and 
other outcomes at birth and through 7 years 
of age, with follow-up completed for approxi-
mately 75% of the children born into the 
study. All mothers provided verbal consent to 
participate (Hardy 2003). The present study 
was approved by an institutional review board 
at the National Institutes of Health.
To evaluate our hypothesis, we used data 
from a nested case–control study of cryp-
torchidism and hypospadias among sons 
within the CPP. Details of the nested case–
control study have been described previously 
(Longnecker et al. 2002). Inclusion criteria 
were based on the characteristics of the mother 
and infant. The sole maternal inclusion crite-
rion was the availability of a 3-mL aliquot of 
third-trimester serum. Inclusion criteria based 
on the characteristics of the infant included 
alive at birth, male sex, and singleton birth. 
Of the 28,444 boys born to mothers enrolled 
prospectively in the CPP cohort, 6,097 were 
not eligible for inclusion in the current analy-
sis because there was no maternal 3-mL ali-
quot of third-trimester serum available (n = 
5,389), the son was not a singleton (n = 441), 
or the son was not live born (n = 267). Among 
the eligible 22,347 boys, there were 241 cases 
of cryptorchidism and 214 cases of hypospa-
dias. Five boys had both cryptorchidism and 
hypospadias and were included in each group 
for analysis. For comparison, we randomly 
selected a group of boys (n = 599) from the 
remaining eligible boys without a diagnosis of 
cryptorchidism and/or hypospadias. Controls 
were selected so that the control:case ratio 
would be > 2:1 for each case group.
Hypospadias (urethral opening on the 
ventral side of the penis) was defined as having 
a diagnosis any time within the first 7 years 
of life. The degree of hypospadias was not 
captured in the medical records. The diagnosis 
of cryptorchidism (failure of one or both tes-
ticles to descend into the scrotum) was made 
by pediatricians based on serial examinations 
that included inspection and palpation of the 
genitalia. We defined cryptorchidism as hav-
ing had a diagnosis of undescended testis(es) at 
any time during the first year of life. Boys with 
undescended testis(es) after the first year of life 
were not considered cryptorchid because they 
may have had retractile testes. Among the boys 
with undescended testicle(s) at birth (n = 138), 
all but one had documented orchiopexy or a 
subsequent observation of cryptorchidism in 
at least one of the three subsequent examina-
tions (ages 4 months, 1 year, 7 years). For the 
remaining boys diagnosed as cryptorchid dur-
ing the first year of life (n = 103), study records 
indicated that the testicles were descended at 
birth, suggesting that these boys may have 
had acquired, rather than congenital, unde-
scended testis (Barthold and Gonzalez 2003). 
To evaluate whether a relationship with oxy-
chlordane or trans-nonachlor varied by type 
of cryptorchidism, we considered boys with 
testis(es) descended at birth separately in an 
additional analysis.
For analyses in CPP, the socioeconomic 
index was calculated as the mean of three per-
centile scores: education of head of the house-
hold, occupation of head of the household or 
chief wage earner, and family income. The 
score used to calculate the percentile for an 
occupation was based on the percentiles of 
education and income among persons with 
the same occupation (Myrianthopoulos and 
French 1968).
Laboratory assays. Serum levels of chlor-
dane (trans-nonachlor and oxychlordane) were 
measured at the Centers for Disease Control 
and Prevention (CDC) after solid-phase extrac-
tion cleanup and dual-column gas chroma-
tography using electron capture (Brock et al. 
1996). Serum levels of p,p´-dichloro  diphenyl-
dichloroethylene (p,p´-DDE) and 11 poly-
chlorinated biphenyls (PCBs) were measured in 
the same laboratory, and the laboratory meth-
ods have been described previously (Longnecker 
et al. 2002; McGlynn et al. 2009a). Serum cho-
lesterol and triglycerides were measured using 
standard enzymatic assays.
The between-assay coefficient of varia-
tion was 25% for trans-nonachlor and 
20% for oxychlordane. These were deter-
mined at concentrations of 0.52 and 0.57 
μg/L (301 batches), respectively. Limits of 
detection (LODs) were 0.28 μg/L for trans-
nonachlor and 0.20 μg/L for oxychlordane; 
29% of the values for trans-nonachlor were 
below that value, whereas 31% of the values 
for oxychlordane were below the LOD. For 
values below the LOD, we used the signal 
recorded by the instrument, when available, 
because it is thought that the signals below 
the instrument’s LOD yield better estimates 
of true concentration than imputed values 
(Chevrier et al. 2010). Undetected values 
were set to missing.
Statistical analysis. Of the 1,054 total 
subjects (241 cryptorchid, 214 hypo  spadias, 
599 controls), 3% were missing data on 
trans-nonachlor. Of those with data on trans-
nonachlor, 6% were missing data on other 
covariates, and 5% were also missing data on 
oxychlordane. A total of 971 (217 cryptorchid, 
197 hypospadias, 557 controls) subjects 
were included in the analysis of trans-non-
achlor, and a total of 919 (206 cryptorchid, 
181 hypospadias, 532 controls) were included 
in the analysis of oxychlordane.
We categorized trans-nonachlor and oxy-
chlordane concentrations according to the 
quartile distributions in controls, with the 
lowest quartile serving as the reference cat-
egory. Odds ratios (ORs) and 95% confi-
dence intervals (CIs) for the association 
between trans-nonachlor or oxychlordane 
and cryptorchidism or hypospadias were esti-
mated using conditional logistic regression 
conditioned on study center (12 strata). We 
assessed a linear trend across quartile catego-
ries by including a single independent vari-
able taking the value of the corresponding 
median of the category. Models were adjusted 
for serum p,p´-DDE as a five-stratum cate-
gorical variable, total PCBs as a four-stratum 
categorical variable, and serum triglycerides 
and cholesterol as continuous variables. We 
included serum triglycerides and cholesterol 
as independent variables in all statistical analy-
ses to account for interindividual variations 
in serum lipid concentration. The results of 
analyses that modeled lipid-adjusted trans-
nonachlor and oxychlordane produced results 
similar to those presented. We included serum 
lipids as a covariate in our model rather than 
using lipid-standardized chlordane concen-
trations because the latter may be prone to 
bias, depending on the underlying mecha-
nism of the chlordane–lipid disease associa-
tion (Gaskins and Schisterman 2009).
All models included trans-nonachlor 
or oxychlordane as the main exposure and 
were adjusted for total PCBs, p,p´-DDE, 
triglycerides, and cholesterol as a priori 
selected variables. Additional variables were 
assessed as potential confounders using the 
change in estimate method (Maldonado and 
Greenland 1993), starting with all variables 
in the models with deletion of one by one 
in a stepwise manner. If, on deletion, the 
OR for the contrast of the highest-to-lowest 
chlordane strata or the OR from the trend 
test changed by ≥ 15%, the factor was con-
sidered a confounder and was included in 
the adjusted analyses. Potential confounding 
factors included race, maternal age, mater-
nal history of previous live birth, season of Trabert et al.
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birth, socioeconomic index, smoking dur-
ing pregnancy, and gestational hypertension, 
as defined in Table 1. Additional potential 
confounding factors included the categorical 
variables (yes/no) hyperemesis gravidarum, 
history of infertility, menstrual cycle irregu-
larity, estrogen use during pregnancy, and 
progesterone use during pregnancy, as well as 
the continuous variables age at menarche and 
weight gain during pregnancy. Socioeconomic 
index was the only variable that changed the 
OR by ≥ 15%. We also considered the effects 
of adjustment for the continuous variables 
birth weight and placental weight and the 
categorical variables preterm birth and small-
for-gestational-age, even though these were 
potentially intermediate variables.
We evaluated effect modification by 
maternal age, race, smoking, prepregnancy 
body mass index (BMI), previous live births, 
triglycerides, cholesterol, serum p,p´-DDE, 
total PCBs, gestational hypertension, and 
socioeconomic index, using the cross-prod-
uct terms. Variables were coded as defined in 
Table 1, with the exception of prepregnancy 
BMI, which was coded as < 25, 25–29.9, 
≥ 30 kg/m2. We supplemented evaluation of 
effect modification by categorical variables 
with more than two categories by compar-
ing the model fit statistics for models with 
and without the cross-product terms. If the 
p-value associated with the interaction term 
based on the likelihood ratio test had a value 
< 0.10, the degree of potential effect modi-
fication was further evaluated by examining 
tables stratified by the potentially modify-
ing factor(s). Statistical significance was set at 
p < 0.05 for main effects based on two-sided 
tests. Statistical analyses were conducted using 
SAS statistical software package, version 9.2 
(SAS Institute Inc., Cary, NC, USA).
Results
The distribution of selected demographic 
and health characteristics of the mothers and 
sons stratified by study group are provided 
in Table 1. For both cryptorchid and hypos-
padias case groups, a higher percentage of 
case boys than control boys were white, born 
preterm, and small-for-gestational-age (birth 
weight < 10th percentile). The distribution of 
other potential confounding factors according 
to case–control status has been published pre-
viously (Longnecker et al. 2002).
The median maternal serum concentra-
tions of trans-nonachlor, oxychlordane, DDE, 
total PCBs, cholesterol, and triglycerides 
for each study group are shown in Table 2. 
The median level of maternal serum trig-
lycerides was slightly lower for hypospadias 
cases (188 μg/L) compared with cryptorchid 
cases (204 μg/L) or controls (204 μg/L). The 
Spearman correlation coefficients of trans-
nonachlor, oxychlordane, DDE, total PCBs, 
cholesterol, and triglycerides are provided in 
Table 3. All of the exposures evaluated were 
positively correlated, with the strongest corre-
lation between trans-nonachlor and oxychlor-
dane (r = 0.78), as expected. trans-Nonachlor 
was moderately associated with DDE 
(r = 0.52), while the remaining compounds 
were less correlated (r = 0.08–0.46).
Table 4 provides the adjusted ORs for 
trans-nonachlor and oxychlordane quartiles 
conditioned on study center and adjusted 
for serum DDE concentration, total PCBs, 
triglycerides, cholesterol, and socioeconomic 
index. For cryptorchidism, the quartile-
specific ORs for oxychlordane or trans-non-
achlor were close to the null as well as not 
statistically significant. Similarly for hypos-
padias, the quartile-specific ORs for trans-
nonachlor and oxychlordane were close to 
the null as well as not statistically significant. 
Table 1. Characteristics of mothers and sons according to case–control status of the son, CPP, 1959–1965.
Characteristic Cryptorchidism (n = 217) Hypospadias (n = 197) Control (n = 557)
Race (%)
White 57.6 50.8 46.5
Black 41.5 43.7 47.8
Other 0.9 5.6 5.7
Gestation (week)
Median (IQR) 39 (37–40) 39 (37–41) 39 (38–40)
Preterm birth (%) 19.3 20.5 13.8
Birth weight (g)
Median (IQR) 3,232 (2,863–3,629) 3,147 (2,722–3,487) 3,260 (2,948–3,600)
Small for gestational age (%) 10.7 19.9 5.0
Maternal age (years)
Median (IQR) 24 (21–30) 23 (20–29) 22 (20–28)
Previous live births (%)
0 26.3 31.0 30.3
1 23.0 21.8 22.8
≥ 2 50.7 47.2 46.9
Season of birth (%)
January–March 24.4 17.3 24.6
April–June 28.1 25.4 24.2
July–September 24.9 29.9 25.9
October–December 22.6 27.4 25.3
Socioeconomic index
Median (IQR) 4.7 (3.3–6.3) 4.7 (3.0–6.3) 4.7 (3.3–6.0)
Prepregnancy BMI
Median (IQR) 22.2 (20.3–25.0) 21.8 (19.6–24.2) 22.2 (20.0–24.9)
Gestational hypertension (%) 5.9 6.3 6.2
Maternal smoking status (%)
None 50.7 52.0 55.0
1–10 cigarettes per day 32.3 27.0 26.7
> 10 cigarettes per day 17.0 20.9 18.4
Study center (%)
Boston, MA 32.7 27.4 24.6
Buffalo, NY 7.4 4.1 3.8
New Orleans, LA 6.5 4.1 4.7
New York City, NYa 2.3 3.6 3.1
Baltimore, MD 5.5 6.1 7.9
Richmond, VA 7.4 6.1 6.1
Minneapolis, MN 3.7 4.1 5.4
New York City, NYb 1.4 5.1 7.5
Portland, OR 4.1 5.6 7.2
Philadelphia, PA 15.2 23.9 17.6
Providence, RI 10.6 8.1 5.2
Memphis, TN 3.2 2.0 7.0
IQR, interquartile range (quartiles 1–3). 
aColumbia-Presbyterian Medical Center. bNew York Medical College.
Table 2. Maternal serum values by son’s case–control status, CPP, 1959–1965 [median (IQR)].
Characteristic Cryptorchidism (n = 217) Hypospadias (n = 197) Control (n = 557)
trans-Nonachlor (μg/L) 0.36 (0.26–0.52) 0.40 (0.24–0.58) 0.38 (0.25–0.57)
Oxychlordanea (μg/L) 0.29 (0.14–0.47) 0.34 (0.18–0.58) 0.31 (0.16–0.55)
DDE (μg/L) 23.6 (15.9–35.3) 23.8 (16.6–34.4) 24.5 (16.7–37.5)
Total PCBs with imputed congener (μg/L) 2.8 (2.0–3.9) 2.9 (2.1–4.2) 2.7 (1.8–3.9)
Total cholesterol (μg/L) 232 (190–273) 232 (192–277) 234 (197–280)
Triglycerides (μg/L)  204 (161–252) 188 (156–256) 204 (159–259)
IQR, interquartile range (quartiles 1–3). 
aEleven cases of cryptorchidism, 16 cases of hypospadias, and 25 controls were missing data for oxychlordane, respectively.Chlordanes and male congenital anomalies
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We found no significant increase or decrease 
in risk of either cryptorchidism or hypos-
padias with increasing quartile of maternal 
trans-  nonachlor or oxychlordane level (trend 
p-values all > 0.40).
Potential effect modification at a p-value 
of < 0.10 was present for the cryptorchid-
ism–oxychlordane association by smoking, 
the hypospadias–oxychlordane association by 
BMI, and the hypospadias–trans-nonachlor 
association by smoking. After further evalu-
ation in stratified models, there were some 
differences in ORs by smoking or BMI; how-
ever, all estimates were consistent with no 
association. Given that the main effects were 
not indicative of an association, the results 
from the stratified models are not presented.
In subanalyses, we evaluated the associa-
tions between the chlordanes and cryptorchid-
ism and hypospadias among women with no 
history of a live birth. We hypothesized that 
the trans-nonachlor and oxychlordane expo-
sure to the male fetus would be highest in 
this group of women. Although the quartile-
specific ORs were increased slightly compared 
with the corresponding ORs for all women 
(data not shown), there were no significant 
trends with increasing quartile of mater-
nal trans-nonachlor or oxychlordane level 
for either cryptorchidism (trans-nonachlor: 
p-trend = 0.75; oxychlordane: p-trend = 0.97) 
or hypospadias (trans-nonachlor: p-trend = 
0.68; oxychlordane: p-trend = 0.90). Finally, 
after exclusion of the boys (n = 103) whose 
testicles were initially descended at birth, 
the association between chlordane level and 
cryptorchidism was not substantially different 
from the analysis that included all boys with 
cryptorchidism (results not shown).
Discussion
In the present study, a prospective evalua-
tion of chlordane levels during pregnancy and 
cryptorchidism or hypospadias, the results do 
not support an association between chlordane 
levels and cryptorchidism or hypospadias. 
Further, the lack of association was consis-
tent in the subgroup of primiparous women. 
The median serum concentration of trans-
nonachlor in the United States was 14.8 ng/g 
lipid in 2003–2004, the most recent years for 
which data are available; the median of oxy-
chlordane was 10.3 ng/g lipid (CDC 2011). 
The median serum concentrations of trans-
nonachlor and oxychlordane were 48.0 ng/g 
lipid and 37.5 ng/g lipid, respectively, in the 
present study samples that were collected in 
the 1960s. This suggests that current low-level 
chlordane exposure is unlikely to be related to 
the development of either condition.
To our knowledge, this is the first epi-
demiologic evaluation of the association 
between chlordane levels and hypospadias 
and only the second such study of the asso-
ciation between chlordane levels and cryp-
torchidism. Using breast milk as a proxy for 
maternal exposure, Damgaard et al. (2006) 
evaluated persistent pesticide concentrations 
in milk samples collected from mothers of 
cryptorchid boys (n = 62) and healthy boys (n 
= 68). Maternal milk levels of trans-chlordane 
were slightly higher in mothers of cryptorchid 
boys than mothers of healthy boys; however, 
the overall exposure was very low (0.04 ng/g 
lipid in controls) (Damgaard et al. 2006). The 
investigators reported no relationship between 
oxychlordane and cryptorchidism and a 
border  line significant association between 
cis-chlordane and cryptorchidism. However, 
the percent detection for cis-chlordane was 
only 30.8%, so median concentrations were 
not reported (Damgaard et al. 2006). Our 
finding of no association between oxychlor-
dane level and cryptorchidism is consistent 
with that of Damgaard and colleagues. We 
did not evaluate trans- or cis-chlordane; how-
ever, we report no association between trans-
  nonachlor, another chlordane derivative, and 
cryptorchidism.
Teratogenic effects of chlordane expo-
sure have not been observed in animal studies 
(Abadin et al. 1994). However, chlordane 
exposures has been shown to affect repro-
duction in test animals, delaying puberty, 
disrupting estrous cycling in females, and 
reducing fertility by as much as 50% (Welch 
et al. 1971). Furthermore, chlordane is clas-
sified as potentially carcinogenic to humans 
(Group 2B) by the International Agency for 
Research on Cancer (IARC 2001) and has 
been associated with risk of TGCT (Hardell 
et al. 2003; McGlynn et al. 2009b; Purdue 
et al. 2009). Although chlordane may be a 
carcinogen, both animal data and the present 
study suggest it is not a teratogen.
The present study has several strengths. 
The major advantages were that the study was 
a large and prospective evaluation of chlor-
dane exposure and congenital malformations. 
This study has several potential weaknesses 
that merit consideration. Chlordane levels 
were measured on samples stored for approxi-
mately 40 years. However, prior studies of 
freeze–thaw cycles have demonstrated that 
chlordane levels are quite stable over time 
(Becker et al. 1997). In addition, cholesterol 
and triglyceride levels were in the expected 
range, suggesting that substantial degrada-
tion had not occurred. The chlordane con-
centrations for this study were measured in 
Table 3. Spearman correlation coefficients of selected covariates, CPP, 1959–1965.
trans-Nonachlor Oxychlordane DDE Total PCBs Total cholesterol Triglycerides
trans-Nonachlor (μg/L) 1.00
Oxychlordane (μg/L) 0.78 1.00
DDE (μg/L) 0.52 0.38 1.00
Total PCBs (μg/L) 0.38 0.46 0.37 1.00
Total cholesterol (μg/L) 0.10 0.12 0.15 0.25 1.00
Triglycerides (μg/L) 0.11 0.12 0.08 0.15 0.36 1.00
Table 4. Adjusted ORs and 95% CIs for cryptorchidism and hypospadias in relation to maternal oxychlordane and trans-nonachlor levels (μg/L), CPP, 1959–1965.
Cryptorchidism Hypospadias
Chlordane (quartiles)a Control (n) Case (n) Unadjusted OR Adjusted ORb (95% CI) Case (n) Unadjusted OR Adjusted ORb (95% CI)
trans-Nonachlor (µg/L)
0.00 to < 0.25 134 47 1.00 (reference) 1.00 (reference) 50 1.00 (reference) 1.00 (reference)
0.25 to < 0.38 139 67 1.25 1.27 (0.85, 1.90) 44 0.83 0.84 (0.54, 1.33)
0.38 to < 0.57 142 62 1.33 1.46 (0.93, 2.30) 52 1.00 1.04 (0.64, 1.70)
≥ 0.57 142 41 1.10 1.22 (0.70, 2.12) 51 0.99 1.08 (0.62, 1.89)
Trend testc 557 217 0.55 197 0.60
Oxychlordane (µg/L)
0.00 to < 0.16 131 54 1.00 (reference) 1.00 (reference) 38 1.00 (reference) 1.00 (reference)
0.16 to < 0.31 131 56 0.95 0.90 (0.60, 1.35) 47 1.12 1.06 (0.66, 1.69)
0.31 to < 0.55 137 51 0.90 0.91 (0.59, 1.42) 44 1.03 1.07 (0.64, 1.80)
≥ 0.55 133 45 0.94 0.95 (0.55, 1.64) 52 1.15 1.24 (0.69, 2.22)
Trend testc 532 206 0.90 181 0.46
aQuartile cut points were defined based on 557 and 532 controls for trans-nonachlor and oxychlordane, respectively. bAdjusted ORs and 95% CIs are from conditional logistic regression 
models adjusted for serum DDE concentration (five categories), total PCBs (four categories), triglycerides, cholesterol, and socioeconomic index. cOrdinal test across four categories 
using the median value within each group.Trabert et al.
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third-trimester samples; the critical window 
of exposure might be earlier for hypospadias, 
likely mid-to-late first trimester (Husmann 
2002). However, third-trimester assays should 
reflect first-trimester exposure, given the 
long biological half-life of chlordane (Abadin 
et al. 1994). In the CPP, the prevalence of 
cryptorchidism and hypospadias among 
males within the first year of life was 56 
per 10,000 and 41 per 10,000, respectively 
(Myrianthopoulos and Chung 1974). These 
prevalences were higher than in other U.S. 
populations (cryptorchidism: 19 per 10,000; 
hypospadias: 21 per 10,000) (Paulozzi 1999). 
This difference was likely the result of reduced 
misclassification in CPP, given that congeni-
tal anomalies were identified in a series of 
systematic examinations, whereas birth defect 
registries are typically based on routine reports 
and records only. The ratio of hypospadias to 
cryptorchidism was somewhat higher than 
what might be expected. We included hypo-
spadias diagnosed up until 7 years of age, 
whereas we included cryptorchidism cases 
diagnosed through the first year of life only. 
Further, the medical records did not denote 
the degree of hypospadias, which limited our 
ability to evaluate the relationship of exposure 
and disease severity.
In conclusion, these results provide no 
clear evidence of an effect of in utero chlor-
dane (trans-nonachlor or oxychlordane) levels 
on cryptorchidism or hypospadias, and the 
findings are in line with results from animal 
studies. Further, it is unlikely that current 
chlordane exposure is related to the develop-
ment of either anomaly, because serum chlor-
dane levels at the time of sample collection, 
the early 1960s, were considerably higher than 
levels at present.
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